Penumbra (PEN)
(Delayed Data from NYSE)
$202.04 USD
-2.37 (-1.16%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $201.98 -0.06 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$202.04 USD
-2.37 (-1.16%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $201.98 -0.06 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum C VGM
Zacks News
Wall Street Analysts See a 26.89% Upside in Penumbra (PEN): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Penumbra (PEN) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE Trial
by Zacks Equity Research
Penumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT.
Penumbra's (PEN) Expansion Moves, New Launches Aid Growth
by Zacks Equity Research
Penumbra (PEN) expects to materially increase both revenues and profitability of the international business in the next three years and beyond.
Here's Why Investors Should Hold Encompass Health (EHC) Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of an active expansion strategy and sufficient cash-generating abilities.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.
Wall Street Analysts Think Penumbra (PEN) Could Surge 37.71%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Penumbra (PEN) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down -11.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Penumbra (PEN)
by Zacks Equity Research
Penumbra (PEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.
Penumbra (PEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Penumbra (PEN) will likely report strong Neuro sales growth on the strength of its RED 72 (with the proprietary SENDit technology), RED 43 and BMX81.
Here's Why You Should Hold on to Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Penumbra (PEN) Rides on New Product Offerings as FX Woe Ails
by Zacks Equity Research
Penumbra (PEN) sees an acceleration of Lightning Bolt 7 cases as conversion from surgery, lytics and other mechanical thrombectomy products gains momentum.
Here's Why You Should Invest in Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), driven by growth in vascular and neuro businesses.
Penumbra and Mesa Labs have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Penumbra and Mesa Labs are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovator of neurovascular stroke technologies with 980% EPS growth is a buying opportunity
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Encompass Health (EHC) Up 41% in a Year: More Room for Growth?
by Zacks Equity Research
Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Buy These 3 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Penumbra (PEN), Strategic Education (STRA) and Huron (HURN) are poised to gain.
Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Factors That Make Molina Healthcare (MOH) an Attractive Bet Now
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth on a growing customer base, acquisitions and solid cash reserves.
Wall Street Analysts Believe Penumbra (PEN) Could Rally 27.69%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 27.7% upside potential for Penumbra (PEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.